Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

Kalshi to offer betting on drug trial results and FDA regulatory decisions

16 July 2026 · By · Wire by Fusion42

Published

16 July 2026

Topic

operational-macro

◆ Sectors

Digital Health

◆ Geography

United States

◆ Source

Read at theguardian.com →

◆ Verified

Fusion42 · 16 July 2026 · Fusion42 review

Kalshi, a US prediction market platform, has received regulatory approval to offer betting contracts on FDA drug trial outcomes and regulatory decisions. This opens a new asset class for traders to speculate on biotech and pharma development timelines and approval odds.

This Wire brief sits within Fusion42's coverage of Digital Health.

◆ ◆ The Wire takeaway

If you're raising capital for a clinical-stage biotech company, your trial odds are now tradeable and public. That means investors can hedge their conviction on your molecule separately from your equity—it changes who bids and at what price.

◆ Coverage

1 source · 16 Jul 2026

◆ Related on Wire

◆ Topics

Digital Healthprediction-marketsfda-approvaldrug-trialsbiotech-capitalmarket-information